Filtered By:
Specialty: Cardiology
Condition: Bleeding
Education: Study

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 2151 results found since Jan 2013.

Comparison of Prasugrel and Clopidogrel in Thrombotic Stroke Patients with Risk Factors for Ischemic Stroke Recurrence: An Integrated Analysis of PRASTRO-I, PRASTRO-II, and PRASTRO-III
CONCLUSIONS: This integrated analysis supports the findings of PRASTRO-III. Prasugrel is a promising treatment that results in a numerical reduction in the composite incidence of ischemic stroke, MI, and death from other vascular causes in patients with ischemic stroke who are at a high risk of stroke recurrence. No major safety issues were observed for prasugrel.PMID:37011599 | DOI:10.1159/000529149
Source: Atherosclerosis - April 3, 2023 Category: Cardiology Authors: Takanari Kitazono Masahiro Kamouchi Yuji Matsumaru Toshiaki Shirai Atsushi Takita Takeshi Kuroda Kazumi Kimura Source Type: research

Risks and Benefits of Anticoagulation in Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry Original Articles
Conclusions— In community-based outpatients with AF, use of OAC was high and driven by not only predominantly stroke but also bleeding risk. Stroke risk significantly affects OAC use among those with low bleeding risk, whereas those with high bleeding risk demonstrate consistently lower use of OAC regardless of stroke risk.
Source: Circulation: Cardiovascular Quality and Outcomes - July 16, 2013 Category: Cardiology Authors: Cullen, M. W., Kim, S., Piccini, J. P., Ansell, J. E., Fonarow, G. C., Hylek, E. M., Singer, D. E., Mahaffey, K. W., Kowey, P. R., Thomas, L., Go, A. S., Lopes, R. D., Chang, P., Peterson, E. D., Gersh, B. J., on behalf of the ORBIT-AF Investigators Tags: Coumarins, Arrhythmias, clinical electrophysiology, drugs, Embolic stroke, Risk Factors for Stroke, Anticoagulants Original Articles Source Type: research

CHA2DS2-VASc Recalibration with an Additional Age Category (50-64 years) Enhances Stroke Risk Stratification in Chinese Atrial Fibrillation Patients
CONCLUSION Chinese patients with AF and low CHA2DS2-VASc score were at a disproportionally high risk of ischemic stroke. Chinese patients between 50-64 are at a high risk for stroke despite a low CHA2DS2-VASc score and have low bleeding risk. Only patients aged <50 years are truly low risk. Teaser Chinese atrial fibrillation (AF) patients with low CHA2DS2-VASc scores had a higher ischemic stroke risk than the Caucasians’ counterparts. In this study, we identified that even for Chinese AF patients aged 50-64 years, stroke risk is still markedly elevated. Only patients aged <50 belong to the truly low risk group.
Source: Canadian Journal of Cardiology - May 13, 2016 Category: Cardiology Source Type: research

Novel Drug Targets for Ischemic Stroke Identified Through Mendelian Randomization Analysis of the Blood Proteome.
CONCLUSIONS: Through a systematic MR screen of the circulating proteome, causal roles for five established and two novel biomarkers for ischemic stroke were identified. Side-effect profiles were characterized to help inform drug target prioritization. In particular, SCARA5 represents a promising target for treatment of cardioembolic stroke with no predicted adverse side-effects. PMID: 31208196 [PubMed - as supplied by publisher]
Source: Circulation - June 17, 2019 Category: Cardiology Authors: Chong M, Sjaarda J, Pigeyre M, Mohammadi-Shemirani P, Lali R, Shoamanesh A, Gerstein HC, Paré G Tags: Circulation Source Type: research

Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial
CONCLUSIONS: In this prespecified analysis of the CHANCE-2 trial, the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin in preventing new stroke were consistent in patients with different causes. The influence of stroke cause on benefit of gene-guided antiplatelet therapy should be explored by further trials.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT04078737.PMID:37548009 | DOI:10.1161/STROKEAHA.122.042233
Source: Atherosclerosis - August 7, 2023 Category: Cardiology Authors: Xuewei Xie Jing Jing Xia Meng S Claiborne Johnston Philip M Bath Zixiao Li Xingquan Zhao Liping Liu Yilong Wang Qin Xu Anxin Wang Yong Jiang Hao Li Yongjun Wang CHANCE-2 Investigators Source Type: research

Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-analysis.
CONCLUSIONS: -Carriers of CYP2C19 loss-of-function alleles are at greater risk of stroke and composite vascular events compared with non-carriers among patients with ischemic stroke or TIA treated with clopidogrel. PMID: 27806998 [PubMed - as supplied by publisher]
Source: Circulation - November 1, 2016 Category: Cardiology Authors: Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang QW, Li X, Huang L, Johnston SC, Zhao X, Liu L, Zhang Q, Wang G, Wang Y, Wang Y Tags: Circulation Source Type: research

Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation 　- SAMURAI-NVAF Study.
CONCLUSIONS: Stroke/TIA patients receiving DOACs for secondary prevention were younger and had lower stroke severity and risk indices than those receiving warfarin. Estimated cumulative incidences of stroke and systemic embolism within 2 years were similar between warfarin and DOACs users, but those of death and intracranial hemorrhage were significantly lower among DOAC users. PMID: 29863095 [PubMed - as supplied by publisher]
Source: Circulation Journal - June 1, 2018 Category: Cardiology Authors: Yoshimura S, Koga M, Sato S, Todo K, Yamagami H, Kumamoto M, Itabashi R, Terasaki T, Kimura K, Yagita Y, Shiokawa Y, Kamiyama K, Okuda S, Okada Y, Takizawa S, Hasegawa Y, Kameda T, Shibuya S, Nagakane Y, Ito Y, Matsuoka H, Takamatsu K, Nishiyama K, Fujita Tags: Circ J Source Type: research

Apixaban for Secondary Stroke Prevention: Coexistant Cerebral Atherosclerosis May Increase Recurrent Strokes
CONCLUSIONS: Apixaban is generally safe for patients with ischemic stroke. Increased primary outcomes in stroke patients may in part be attributed to the presence of cerebral atherosclerotic lesions, suggesting that further studies are needed to establish therapeutic strategies in this population.PMID:35135065 | DOI:10.5853/jos.2021.02355
Source: Atherosclerosis - February 8, 2022 Category: Cardiology Authors: Jong S Kim Jaseong Koo Dong-Ick Shin Byung-Su Kim Jei Kim Eung-Gyu Kim Keun-Sik Hong Hyeju Yi Source Type: research

Optimal use of antithrombotic agents in ischemic stroke with atrial fibrillation and large artery atherosclerosis
CONCLUSION: This study demonstrated that OAC monotherapy was associated with lower risks of composite outcome and death in patients at 1-year after ischemic stroke due to AF and atherosclerotic stenosis. In addition, the combination of an antiplatelet agent and OAC had a high risk of major bleeding.PMID:36748980 | DOI:10.1177/17474930231158211
Source: Atherosclerosis - February 7, 2023 Category: Cardiology Authors: Tae Jung Kim Ji Sung Lee Jae Sun Yoon Mi Sun Oh Ji-Woo Kim Soo-Hyun Park Keun-Hwa Jung Hye-Yeon Choi Hyun Young Kim Jee-Hyun Kwon Hahn Young Kim Kyung Yoon Eah Sang Won Han Hyung-Geun Oh Yong-Jae Kim Byoung-Soo Shin Chang Hun Kim Chi Kyung Kim Jong-Moo Pa Source Type: research

The Left Atrial Appendage: Target for Stroke Reduction in Atrial Fibrillation.
Abstract A patient with atrial fibrillation (AF) has a greater than 5% annual risk of major stroke, a 5-fold increase compared to the general population. While anticoagulation remains the standard stroke prevention strategy, the nature of lifelong anticoagulation inevitably carries an increased risk of bleeding, increased stroke during periods of interruption, increased cost, and significant lifestyle modification. Many patients with atrial fibrillation have had their left atrial appendage (LAA) ligated or excised by surgeons during cardiac surgery, a decision based largely on intuition and with no clear evidence ...
Source: Methodist DeBakey Cardiovascular Journal - April 1, 2015 Category: Cardiology Authors: Ramlawi B, Abu Saleh WK, Edgerton J Tags: Methodist Debakey Cardiovasc J Source Type: research

Relationship of Hypertension and Systolic Blood Pressure With the Risk of Stroke or Bleeding in Patients With Atrial Fibrillation: The Fushimi AF Registry.
CONCLUSION: The incidences of stroke/SE and bleeding were higher in AF and hypertension patients with elevated SBP. UMIN Clinical Trials Registry: UMIN000005834. PMID: 28575205 [PubMed - as supplied by publisher]
Source: American Journal of Hypertension - May 30, 2017 Category: Cardiology Authors: Ishii M, Ogawa H, Unoki T, An Y, Iguchi M, Masunaga N, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe M, Akao M Tags: Am J Hypertens Source Type: research

Anticoagulation Resumption After Stroke from Atrial Fibrillation
AbstractThe goal of this paper is to review literature on the topic of anticoagulation resumption after stroke from atrial fibrillation. Following ischemic stroke, the average annual risk of recurrent stroke in a patient with a CHADS2 score of 9 is 12.2%%, translating to an average daily risk of 0.03%%. Oral anticoagulant therapy provides a 75% relative risk reduction. However, in the 2-week period immediately following an acute stroke, this daily risk appears to be elevated. The same period is associated with an increased risk of hemorrhagic transformation of ischemic stroke due to reperfusion, impaired autoregulation, an...
Source: Current Atherosclerosis Reports - May 19, 2019 Category: Cardiology Source Type: research

Efficacy and Safety of Prasugrel by Stroke Subtype: A Sub-Analysis of the PRASTRO-I Randomized Controlled Trial.
CONCLUSIONS: Although statistical significance was not reached, the efficacy of prasugrel was potentially different between stroke subtypes, warranting further studies. PMID: 32493881 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - June 6, 2020 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials
CONCLUSIONS: Adequate blood pressure management is vital to optimally reduce the risk of stroke in patients with atrial fibrillation. The benefits of NOACs over VKAs, also apply to patients with elevated blood pressure.PMID:33685380 | DOI:10.1080/00015385.2021.1882111
Source: Acta Cardiologica - March 9, 2021 Category: Cardiology Authors: Ralf E Harskamp Wim A M Lucassen Renato D Lopes Jelle C L Himmelreich Gianfranco Parati Henk C P M van Weert Source Type: research